Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

Nature Medicine

Volumn 9, Issue 6, 2003, Pages 729-735

  McConkey, Samuel J ^a   Reece, William H H ^a   Moorthy, Vasee S ^a   Webster, Daniel ^a   Dunachie, Susanna ^a   Butcher, Geoff ^b   Vuola, Jenni M ^a   Blanchard, Tom J ^c   Gothard, Philip ^a   Watkins, Kate ^a   Hannan, Carolyn M ^a   Everaere, Simone ^a   Brown, Karen ^a   Kester, Kent E ^d   Cummings, James ^d   Williams, Jackie ^d   Heppner, D Gray ^d   Pathan, Ansar ^a   Flanagan, Katie ^a   Arulanantham, Nirmalan ^a   Roberts, Mark T M ^a   Roy, Michael ^e   Smith, Geoffrey L ^b   Schneider, Joerg ^f   Peto, Tim ^a   Sinden, Robert E ^b   Gilbert, Sarah C ^a   Hill, Adrian V S ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e Powderject Vaccines   (United States)

^f Oxxon Pharmaccines   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; PLASMID DNA; PREERYTHROCYTIC MALARIA ANTIGEN; THROMBOSPONDIN RELATED ADHESION PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; MALARIA FALCIPARUM; NONHUMAN; NORMAL HUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SIDE EFFECT; SPOROZOITE; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, PROTOZOAN; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MALARIA, FALCIPARUM; PEPTIDES; PLASMIDS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

ANIMALIA; PLASMODIUM FALCIPARUM; PROTOZOA; VACCINIA VIRUS;

EID: 0038714287     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm881     Document Type: Article

References (44)

1. + T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18, 275-308 (2000).
2. Kaech, S.M., Wherry, E.J. & Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2, 251-262 (2002).
3. Parker, D.C. T cell-dependent B cell activation. Annu. Rev. Immunol. 11, 331-360 (1993).
4. Doolan, D.L. & Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453-1462 (2000).
5. Guidotti, L.G. et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25-36 (1996).
6. + cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood 99, 590-599 (2002).
7. Winter, H., Hu, H.M., Urba, W.J. & Fox, B.A. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J. Immunol. 163, 4462-4472 (1999).
8. Becker, C. et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat. Med. 7, 1159-1162 (2001)
9. Seki, N. et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168, 3484-3492 (2002).
10. Zwaveling, S. et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002).
11. Bertoletti, A. et al. HLA class I restricted human cytotoxic T cells recognise endogenously synthesised hepatitis B virus nucleocapsid antigen. Proc. Natl. Acad. Sci. USA 88, 10445-10449 (1991).
12. Boni, C. et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102, 968-975 (1998).
13. Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476-480 (1998).
14. + type 1 responses in humans by a malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 98, 10817-10822 (2001).
15. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764-778 (2000).
16. Gupta, K. et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J. Acquir. Immune Defic. Syndr. 29, 254-261 (2002).
17. Lalvani, A. et al. Potent induction of focused Thl-type cellular and humoral immune responses by RTS/S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. 180, 1656-1664 (1999).
18. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397-402 (1998).
19. Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445 (1998).
20. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69, 681-686 (2001).
21. + T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170, 29-38 (1999).
22. Gilbert, S.C. et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous primeboost immunisation regimes. Vaccine 20, 1039-1045 (2002).
23. Gilbert, S.C. et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 15, 1280-1284 (1997).
24. Sullivan, N.J., Sanchez, A., Rollin, P.E., Yang, Z.Y. & Nabel, G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609 (2000).
25. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
26. Marshall, E. Renewed assault on an old and deadly foe. Science 290, 428-430 (2000).
27. Hill, A.V.S. et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 352, 595-600 (1991).
28. Herrington, D. et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am. J. Trop. Med. Hyg. 45, 539-547 (1991).
29. Hoffman, S.L. et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 244, 1078-1081 (1989).
30. Robson, K.J. et al. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 335, 79-82 (1988).
31. Moorthy, V.S. et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 21, 2004-2011 (2003).
32. Chulay, J.D. et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am. J. Trop. Med. Hyg. 35, 66-68 (1986).
33. Ponnudurai, T., Meuwissen, J.H.E.T., Leeuwenberg, A.D.E.M., Verhave, J.P. & Lensen, A.H.W. The production of mature gametocytes of Plasmodium falciparum in continuous cultures of different isolates infective to mosquitoes. Trans. R. Soc. Trop. Med. Hyg. 76, 242-250 (1982).
34. Simpson, J.A., Aarons, L., Collins, W.E., Jeffery, G.M. & White, N.J. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology 124, 247-263 (2002).
35. Davis J.R. et al. Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3. Trans. R. Soc. Trop. Med. Hyg. 83, 748-750 (1989).
36. Schneider, J. et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 19, 4595-4602 (2001).
37. Robson, K.J. et al. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 58, 81-89 (1998).
38. Hermsen, C.C. et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol. Biochem. Parasitol. 118, 247-251 (2001).
39. Davis J.R. et al. Estimate of Plasmodium falciparum sporozoite content of Anopheles stephensi used to challenge human volunteers. Am. J. Trop. Med. Hyg. 40, 128-130 (1989).
40. Stoute, J.A. et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139-1144 (1998).
41. Flanagan, K. et al. Ex-vivo interferon y immune response to TRAP in coastal Kenyans: longevity and risk of P. falciparum infection. Am. J. Trop. Med. Hyg (in press).
42. Plebanski, M. et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur. J. Immunol. 28, 4345-4355 (1998).
43. Stittelaar, K.J. et al. Safety of modified vaccinia virus Ankara (MVA) in immunesuppressed macaques. Vaccine 19, 3700-3709 (2001).
44. Chakrabarti, S., Brechling, K. & Moss, B. Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5, 3403-3409 (1985).